75,416 results match your criteria Lung Cancer Non-Small Cell


Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.

Cancer Med 2019 Apr 24. Epub 2019 Apr 24.

Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.

Background: Although oncogenic driver mutations were thought to be mutually exclusive in non-small cell lung cancer (NSCLC), certain tumors harbor co-occurring mutations and represent a rare molecular subtype. The evaluation of the clinical features and therapeutic response associated with this NSCLC subtype will be vital for understanding the heterogeneity of treatment response and improving the management of these patients.

Methods: This retrospective study included 3774 samples from patients diagnosed with NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2183DOI Listing

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Thorac Cancer 2019 Apr 23. Epub 2019 Apr 23.

Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.

According to multiple studies, the objective response rate of PD-1/PD-L1 inhibitors in the second-line treatment of unscreened non-small cell lung cancer (NSCLC) is only approximately 20%. Predictive biomarkers of treatment efficacies are still under investigation. In selected NSCLC patients with PD-L1 expression ≥ 50%, the response rate of pembrolizumab in first-line treatment can reach 44. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13078DOI Listing

Gene polymorphisms of SFTPB rs7316, rs9752 and PAOX rs1046175 affect the diagnostic value of plasma Pro-SFTPB and DAS in Chinese Han non-small-cell lung cancer patients.

J Cell Biochem 2019 Apr 23. Epub 2019 Apr 23.

Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, China.

Plasma pro-surfactant protein B (pro-SFTPB) and N1,N12-diacetylspermine (DAS) can be used as markers for the diagnosis of non-small-cell lung carcinoma (NSCLC). Whether the genetic diversity affects the application value of Pro-SFTPB and DAS as a diagnostic marker for NSCLC is still unknown. This study aims to explore the relationship between SFTPB rs7316, rs9752 and PAOX rs1046175 gene polymorphisms and the diagnostic value of plasma Pro-SFTPB and DAS in patients with Chinese Han lung cancer. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.28741
Publisher Site
http://dx.doi.org/10.1002/jcb.28741DOI Listing
April 2019
1 Read

Better Survival After 4L Lymph Node Dissection for Early-Stage, Left-Sided, Non-small Cell Lung Cancer: Are We Debating a False Duality?

Ann Surg Oncol 2019 Apr 23. Epub 2019 Apr 23.

Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07382-zDOI Listing

Clinical T categorization in stage IA lung adenocarcinomas: prognostic implications of CT display window settings for solid portion measurement.

Eur Radiol 2019 Apr 23. Epub 2019 Apr 23.

Department of Radiology, Seoul National University College of Medicine, 101, Daehak-ro, Jongno-gu, Seoul, 03080, South Korea.

Objectives: Our study aimed at evaluating the prognostic implications of lung and mediastinal CT display window settings for solid portion measurements on the eighth-edition lung cancer staging system's clinical T (cT) categorization.

Methods: We retrospectively analyzed 691 surgically treated patients from 2009 to 2015 for clinical stage IA lung adenocarcinomas. Solid portions were measured at the lung and mediastinal window settings, respectively, and cT categories were determined for each measurement (cT and cT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06216-6DOI Listing

ProGRP as early predictive marker of non-small-cell lung cancer to small-cell lung cancer transformation after EGFR-TKI treatment.

Respir Med Case Rep 2019 13;27:100837. Epub 2019 Apr 13.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

We report a case of non-small-cell lung cancer (NSCLC) to small-cell lung cancer (SCLC) transformation after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The patient was a man who diagnosed with EGFR-mutant advanced NSCLC. After he was introduced afatinib, his tumor had been reduced by the treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.100837DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468187PMC

Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.

Can Respir J 2019 20;2019:5315903. Epub 2019 Mar 20.

Department of Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-Machi, Kanazawa 920-8641, Japan.

Background: Standard chemotherapy for advanced non-small-cell lung cancer (NSCLC) with preexisting interstitial lung disease (ILD) has not yet been established. Although a combination of carboplatin and paclitaxel is most frequently used for patients with advanced NSCLC and ILD, the safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) are yet to be elucidated.

Objectives: This study aimed to evaluate the safety and efficacy of carboplatin plus nab-paclitaxel for advanced NSCLC with ILD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5315903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446117PMC

Preliminary comparison of neuropsychological performance in patients with non-small-cell lung cancer treated with chemotherapy or targeted therapy.

Neuropsychiatr Dis Treat 2019 28;15:753-761. Epub 2019 Mar 28.

Department of Psychology, Chung Shan Medical University, Taichung, Taiwan,

Purpose: This cross-sectional pilot study aimed to compare the effects of chemotherapy and targeted therapy on neuropsychological performance and psychiatric symptoms in patients with non-small-cell lung cancer (NSCLC).

Patients And Methods: A total of 113 patients with NSCLC were recruited. According to their type of cancer treatment, the patients were classified into chemotherapy (n=40), targeted therapy (n=33), and untreated control (n=40) groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/NDT.S194642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446983PMC

Efficacy and toxicities of combination maintenance therapy in the treatment of advanced non-small-cell lung cancer: an up-to-date meta-analysis.

Biosci Rep 2019 Apr 23. Epub 2019 Apr 23.

The people's hospital of Tongwei county, Dingxi, China.

Background Single agent maintenance therapy has been approved for the treatment of advanced non-small-cell lung cancer due to its potential survival benefits, but whether combined maintenance therapy would improve the survival of advanced NSCLC remains undetermined.MethodsRelevant trials were identified by searching electronic databases and conference meetings. Prospective randomized controlled trials (RCTs) assessing combination maintenance therapy in advanced NSCLC patients were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20182464DOI Listing

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.

Oncologist 2019 Apr 23. Epub 2019 Apr 23.

Medical Oncology 2, Veneto Institute of Oncology IOV, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy

Background: Immune-checkpoint inhibitors (ICIs) are now standard of care for advanced non-small cell lung cancer (NSCLC). Unfortunately, many patients experience immune-related adverse events (irAEs), which are usually mild and reversible, but they require timely management and may be life threatening. No predictive markers of irAEs are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0563DOI Listing

Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.

Radiother Oncol 2019 Mar 27;135:141-146. Epub 2019 Mar 27.

Maastricht University Medical Center, Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands.

Background: Stage III non-small cell lung cancer (NSCLC) still has a poor prognosis. Prior studies with individualized, accelerated, isotoxic dose escalation (INDAR) with 3D-CRT showed promising results, especially in patients not treated with concurrent chemo-radiotherapy. We investigated if INDAR delivered with IMRT would improve the overall survival (OS) of stage III NSCLC patients treated with concurrent chemotherapy and radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.03.009DOI Listing

Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.

Radiother Oncol 2019 Mar 20;135:115-119. Epub 2019 Mar 20.

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.

Introduction: Post-treatment lymphocytopaenia is a recognized complication of thoracic radiotherapy likely due to irradiation of a large volume of circulatory blood. We hypothesize that post-treatment absolute lymphocyte count (ALC) is associated with integral body dose and overall survival (OS) in lung cancer patients treated with radical radiotherapy.

Materials And Methods: Data on clinicopathological variables, dosimetric parameters, and pre and post-treatment blood counts were collected retrospectively in 217 lung cancer patients (131 with non-small cell lung cancer and 86 with small cell lung cancer) treated with radical radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.03.008DOI Listing

Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: Evaluation of the added prognostic value for overall survival and locoregional recurrence.

Radiother Oncol 2019 Apr 11;136:78-85. Epub 2019 Apr 11.

The D-Lab: Decision Support for Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, the Netherlands.

Background And Purpose: The prognostic value of radiomics for non-small cell lung cancer (NSCLC) patients has been investigated for images acquired prior to treatment, but no prognostic model has been developed that includes the change of radiomic features during treatment. Therefore, the aim of this study was to investigate the potential added prognostic value of a longitudinal radiomics approach using cone-beam computed tomography (CBCT) for NSCLC patients.

Materials And Methods: This retrospective study includes a training dataset of 141 stage I-IV NSCLC patients and three external validation datasets of 94, 61 and 41 patients, all treated with curative intended (chemo)radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.03.032DOI Listing

The single nucleotide variant rs2868371 associates with the risk of mortality in non-small cell lung cancer patients: A multicenter prospective validation.

Radiother Oncol 2019 Apr 6;136:29-36. Epub 2019 Apr 6.

Department of Radiation Oncology, University Hospital Virgen del Rocío, Seville, Spain; Instituto de Biomedicina de Sevilla (IBIS/HUVR/CSIC/Universidad de Sevilla), Spain. Electronic address:

Background And Purpose: Definitive radiation therapy (RT) with or without chemotherapy has become the standard treatment for non-metastatic unresectable non-small cell lung cancer (NSCLC). However, treatment outcomes can differ substantially and patients' genetic background could play a crucial role. Potential associations between single-nucleotide polymorphisms (SNP) in Heat shock protein beta-1 (HSPB1) and survival have been reported in prior single-institution retrospective reports. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.03.025DOI Listing

Differential inflammatory response dynamics in normal lung following stereotactic body radiation therapy with protons versus photons.

Radiother Oncol 2019 Apr 20;136:169-175. Epub 2019 Apr 20.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA. Electronic address:

Background And Purpose: To compare time-dependent changes in lung parenchyma of early-stage non-small cell lung carcinoma (NSCLC) patients after stereotactic body radiation therapy with protons (SBPT) or photons (SBRT).

Materials And Method: We retrospectively identified NSCLC patients treated with SBPT and matched each one with a SBRT patient by patient, tumor, and treatment characteristics. Lung parenchyma on serial post-treatment chest computer tomography (CT) scans was deformably registered with the treatment plan to analyze lung density changes as function of dose, quantified by Houndsfield Unit (HU)/Gy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.04.004DOI Listing

Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer.

Radiother Oncol 2019 Apr 17;136:136-142. Epub 2019 Apr 17.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address:

Background & Purpose: We report disease control, survival, and toxicity in patients with advanced inoperable non-small cell lung cancer (NSCLC) receiving concurrent chemotherapy and intensity-modulated proton therapy (IMPT) at a single institution.

Material And Methods: All patients were treated with IMPT with concurrent chemotherapy. Endpoints assessed were local, regional, and distant control, disease-free survival (DFS), and overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.03.029DOI Listing

Enhanced recovery after thoracic surgery is associated with improved adjuvant chemotherapy completion for non-small cell lung cancer.

J Thorac Cardiovasc Surg 2019 Mar 21. Epub 2019 Mar 21.

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex. Electronic address:

Objective: Enhanced recovery after surgery integrates multiple evidence-based interventions to accelerate postoperative recovery. We hypothesized that enhanced recovery after surgery would also facilitate adjuvant chemotherapy for non-small cell lung cancer.

Methods: An enhanced recovery after surgery pathway was implemented at a single institution, starting with a transitional rollout in 2012 and full rollout in 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2019.03.009DOI Listing

[Advances of the Correlation between Driver Gene Status and Immunotherapy 
in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi 2019 Apr;22(4):233-238

The Forth Hospital of Hebei Medical University, Shijiazhuang 050011, China.

In recent years, the checkpoint inhibitors targeted programmed cell death 1 (PD-1) and its ligand 1 (PD-1 ligand, PD-L1) achieved landmark significance in treating a variety of cancers including non-small cell lung cancer (NSCLC). However, current immunotherapy is not precise enough, only 15%-20% of the unselected patients can benefit from the therapy, and there is a possibility of hyperprogression (HP). Therefore, how to select the dominant population is crucial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.06DOI Listing

[Clinical Application of Plasma miR-34b-3p and miR-302a-5p in the Diagnosis of Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi 2019 Apr;22(4):216-222

Department of Epidemiology, Beijing Chest Hospital, Capital Medical University, 
Beijing 101149, China.

Background: MicroRNA is a kind of single-stranded non-coding RNA whose length is about 22 nucleotides and its abnormal expression is related to disease closely. This study is aiming to explore the relative expression of miR-34b-3p and miR-302a-5p in the plasma of non-small cell lung cancer (NSCLC) patients and its clinical value.

Methods: The levels of miR-34b-3p and miR-302a-5p in plasma were detected by real-time polymerase chain reaction (RT-PCR) in 86 patients with NSCLC, 64 patients with pulmonary tuberculosis (PTB) and 39 healthy subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.03DOI Listing

[Study on the Metabolic Reprogramming of Lung Cancer Cells Regulated by Docetaxel Based on Metabolomics].

Zhongguo Fei Ai Za Zhi 2019 Apr;22(4):208-215

Department of Thoracic Surgery, Cancer Hospital, China Medical University, Shenyang 110042, China.

Background: Docetaxel is a commonly used anti-tumor drug in clinic, especially as the first-line drug for advanced non-small cell lung cancer (NSCLC). However, the molecular mechanism of docetaxel against NSCLC is still unclear. Increasing studies have shown that metabolic reprogramming of tumor cells plays an important role in tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.04.02DOI Listing

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level.

BMC Cancer 2019 Apr 23;19(1):369. Epub 2019 Apr 23.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, People's Republic of China.

Background: Intratumoral epidermal growth factor receptor (EGFR) mutational heterogeneity is yet controversial in non-small cell lung cancer (NSCLC) patients. Single-cell analysis provides the genetic profile of single cancer cells and an in-depth understanding of the heterogeneity of a tumor.

Methods: Firstly, single H1975 cells harboring the EGFR L858R mutation were submitted to flow cytometry isolation, nested polymerase chain reaction (nested-PCR) amplification, and direct DNA sequencing to assess the feasibility of single-cell direct DNA sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5555-yDOI Listing

Research on circadian clock genes in non-small-cell lung carcinoma.

Chronobiol Int 2019 Apr 24:1-12. Epub 2019 Apr 24.

e Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China.

Circadian clock genes have become a hot topic in cancer research in recent years, and more and more studies are showing that clock genes are involved in regulating cell proliferation cycle and apoptosis of malignant tumors, neuroendocrine and immune function, and other processes. Lung cancer is a malignant tumor with increasing incidence worldwide. The pathogenesis of lung cancer is extremely complicated and includes genetic factors, living environment, and smoking, and the occurrence of lung cancer is related to the regulation of many oncogenes and tumor suppressor genes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07420528.2018.1509080DOI Listing

Therapeutic Changes in Bilateral Choroidal Metastasis from Non-Small Cell Lung Cancer with Response to Afatinib: A Case Report.

Ocul Immunol Inflamm 2019 Apr 23:1-4. Epub 2019 Apr 23.

b Department of Ophthalmology , The Cancer Institute Hospital Of JFCR , Tokyo , Japan.

A 49-year-old male presented with a three-day onset of blurred vision and metamorphopsia in the left eye. Fundoscopy and OCT images identified multiple subretinal masses with associating serous retinal detachment in both eyes. Bilateral choroidal metastasis was suspected, and further evaluation revealed a mass in the lower left lobe of the lung with multiple metastatic loci. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09273948.2019.1584322DOI Listing

Preparative isolation and purification of steroidal glycoalkaloid from the ripe berries of Solanum nigrum L. by preparative HPLC-MS and ultra high performance liquid chromatography time-of-flight-MS/MS and its anti-non-small cell lung tumours effects in vitro and in vivo.

J Sep Sci 2019 Apr 23. Epub 2019 Apr 23.

School of Pharmaceutical Sciences, Capital Medical University, Beijing, P. R. China.

Overcoming epidermal growth factor receptor resistance is a critical problem that needs to be solved in clinical practice. Drugs that downregulate the fatty acid synthase-epidermal growth factor receptor will become novel treatments for non-small cell lung cancer. Solanum nigrum, extracted with water at 4°C, shows strong cytotoxic activity and inhibits tumour growth in Lewis tumour bearing-mice in a dose-dependent manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jssc.201801165DOI Listing

Six2 promotes non-small cell lung cancer cell stemness via transcriptionally and epigenetically regulating E-cadherin.

Cell Prolif 2019 Apr 22:e12617. Epub 2019 Apr 22.

Cancer Prevention Center, The Second Hospital of Shandong University, Tianqiao District, Jinan, China.

Objectives: The roles and related mechanisms of six2 in regulating non-small cell lung cancer (NSCLC) cells progression are unclear. This work aimed to explore the roles of six2 in NSCLC cell stemness.

Materials And Methods: Kaplan-Meier plotter analysis was used to examine the correlation between six2 expression and the survival of NSCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cpr.12617DOI Listing

Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance.

Ann Surg Oncol 2019 Apr 22. Epub 2019 Apr 22.

Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Objective: The aim of this study was to compare survival outcomes between non-small cell lung cancer (NSCLC) patients with or without 4L node dissection (4LND) and to evaluate the potential patient population who will particularly benefit from 4LND.

Methods: Between January 2009 and December 2015, a total of 2063 patients with primary left-sided NSCLC in the Western China Lung Cancer Database were initially reviewed. After exclusion, 1064 patients were enrolled in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07368-xDOI Listing

Increases in Serial Pretreatment F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy.

Adv Radiat Oncol 2019 Apr-Jun;4(2):429-437. Epub 2018 Nov 26.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.

Purpose: Quantitative changes in positron emission tomography with computed tomography imaging metrics over serial scans may be predictive biomarkers. We evaluated the relationship of pretreatment metabolic tumor growth rate (MTGR) and standardized uptake value velocity (SUVV) with disease recurrence or death in patients with early-stage non-small cell lung cancer treated with stereotactic ablative radiation therapy (SABR).

Methods And Materials: Under institutional review board approval, we retrospectively identified patients who underwent positron emission tomography with computed tomography at diagnosis and staging and simulation for SABR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460103PMC
November 2018

Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC.

Adv Radiat Oncol 2019 Apr-Jun;4(2):422-428. Epub 2019 Jan 24.

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Purpose: Previous studies suggest that stereotactic body radiation therapy (SBRT) is associated with higher toxicity rates for central lung tumors relative to peripheral tumors when using 3 fraction SBRT. The initial results from Radiation Therapy Oncology Group study 0813 suggest a safe toxicity profile of SBRT administered in 5 fractions for central non-small cell lung cancer (NSCLC). We reviewed our institutional data to evaluate the safety and efficacy of SBRT for central NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2019.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460233PMC
January 2019

The Dosimetric Comparisons of CRT, IMRT, ARC, CRT+IMRT, and CRT+ARC of Postoperative Radiotherapy in IIIA-N2 Stage Non-Small-Cell Lung Cancer Patients.

Biomed Res Int 2019 18;2019:8989241. Epub 2019 Mar 18.

Central South University of Xiangya Hospital, Department of Radiation Oncology, Changsha, Hunan 410008, China.

Currently, studies about PORT in stage IIIA-N2 NSCLC patients in recent years have mostly adopted the conformal radiation therapy (CRT) technique, while other modern techniques such as intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT, hereinafter referred to as ARC), helical tomotherapy (HT), and so forth are also developing quickly. In this paper, we intended to compare the dosimetric characteristics of CRT, IMRT, ARC, CRT+IMRT, and CRT+ARC of PORT in stage IIIA-N2 NSCLC patients. Ten patients with stage IIIA-N2 completely resected NSCLC, whom were treated by PORT in the radiotherapy department of our hospital from January 1, 2017, to January 1, 2018, were randomly selected in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/8989241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442440PMC
March 2019
1 Read

Disparities in the Use of Single-fraction Stereotactic Radiosurgery for the Treatment of Brain Metastases From Non-small Cell Lung Cancer.

Cureus 2019 Feb 7;11(2):e4031. Epub 2019 Feb 7.

Radiation Oncology, Henry Ford Hospital, Detroit, USA.

Purpose: Radiation treatment patterns in patients with brain metastases from non-small cell lung cancer (NSCLC) have not been well elucidated. The National Cancer Database (NCDB) was used to evaluate trends in the use of whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) for brain metastasis from NSCLC.

Methods: This NCDB study included patients > 18 years old with metastatic NSCLC treated with single-fraction SRS or WBRT between 2004 and 2014. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/17567-disparities-in-the-use
Publisher Site
http://dx.doi.org/10.7759/cureus.4031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456282PMC
February 2019
1 Read

OTU deubiquitinase 4 is silenced and radiosensitizes non-small cell lung cancer cells via inhibiting DNA repair.

Cancer Cell Int 2019 15;19:99. Epub 2019 Apr 15.

3Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Tianjin Medical University, Tianjin, 300070 China.

Background: Radiotherapy is becoming one major therapeutics for non-small cell lung cancer (NSCLC). Identifying novel radiosensitizers will greatly increase the efficacy of radiotherapy and benefit more patients. OTU deubiquitinase 4 (OTUD4) has been reported involved in DNA damage repair pathways and could be a potential target for chemotherapy therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0816-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466656PMC

Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.

Clin Cancer Res 2019 Apr 22. Epub 2019 Apr 22.

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Tumors are continuously evolving biological systems, and medical imaging is uniquely positioned to monitor changes throughout treatment. Although qualitatively tracking lesions over space and time may be trivial, the development of clinically relevant, automated radiomics methods that incorporate serial imaging data is far more challenging. In this study, we evaluated deep learning networks for predicting clinical outcomes through analyzing time series CT images of patients with locally advanced non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-2495DOI Listing
April 2019
1 Read

[Phenotypical plasticity and targeted therapies in non-small cell lung carcinomas].

Rev Mal Respir 2019 Apr 19. Epub 2019 Apr 19.

Inserm UMR-S 1250 P3Cell, Pathologies Pulmonaires et Plasticité Cellulaire, Université de Reims Champagne-Ardenne, 45, rue Cognacq-Jay, 51092 Reims cedex, France.

Lung cancer is the most diagnosed and deathly type of cancer worldwide. It has a poor prognosis because of a late diagnosis, high metastatic potential and resistance to conventional therapies. Since the 2000s, the emergence of targeted therapies has improved patients' outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmr.2019.03.004DOI Listing

[Therapeutic options for oligoprogressive non-small cell lung cancer].

Rev Mal Respir 2019 Apr 19. Epub 2019 Apr 19.

Département d'oncologie radiothérapie, institut d'oncologie thoracique (IOT), Gustave-Roussy, université Paris-Saclay, 114, rue Vaillant, 94805 Villejuif, France; Université Paris Sud, université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France; Inserm U1030, radiothérapie moléculaire, 94805 Villejuif, France. Electronic address:

Lung cancer is the leading cause of cancer-related mortality and more than half of the cases are diagnosed at a metastatic stage. Major progress in terms of systemic treatments has been achieved in recent decades. Access to new anti-PD-(L) 1 immunotherapies and targeted therapies for non-small cell lung cancer (NSCLC) with oncogenic addiction such as EGFR mutation or ALK rearrangement have led to improved outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmr.2018.04.011DOI Listing
April 2019
1 Read

NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors.

Cytotherapy 2019 Apr 19. Epub 2019 Apr 19.

Seoul National University Cancer Research Institute, Seoul, Republic of Korea; Department of Internal Medicine.

Background: Treatment with tyrosine kinase inhibitors (TKIs) has improved the outcomes for patients with non-small cell lung cancer (NSCLC) harboring targetable driver mutations. However, acquired resistance to TKIs invariably develops within approximately 1 year of treatment by various mechanisms, including gatekeeper mutations, alternative pathway activation and histological transformations. Because immunotherapy is an option for patients with drug-resistant cancers, we generated several TKI-resistant NSCLC cell lines in vitro, and then evaluated the cytotoxicity of NK92-CD16 cells to these resistant cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcyt.2019.03.312DOI Listing

In response to Hsia TC et al. "Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database".

Radiother Oncol 2019 Apr 19. Epub 2019 Apr 19.

Clinical Research Department, Parkview Cancer Institute, 11050 Parkview Circle, Fort Wayne, IN 46845, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.04.001DOI Listing

A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.

Biochem Biophys Res Commun 2019 Apr 19. Epub 2019 Apr 19.

National Translational Science Center for Molecular Medicine, Air Force Medical University, Xi'an, 710032, China; Department of Cell Biology, School of Basic Medicine, Air Force Medical University, Xi'an, 710032, China. Electronic address:

Cluster of differentiation 147 (CD147), a transmembrane protein of the immunoglobulin superfamily, is a potential target of treatment against human non-small cell lung cancer (NSCLC). Although there have been exciting advances in epidermal growth factor receptor (EGFR)-targeted therapy for NSCLC in recent years, additional novel targeted agents are needed to improve the efficiency and to offer more options for patients. Antibody-drug conjugates (ADCs) utilize a chemical linker to conjugate cytotoxic drugs to a monoclonal antibody to maximize the delivery to target cells and minimize the delivery to other normal cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.04.046DOI Listing

HERC4 exerts an anti-tumor role through destabilizing the oncoprotein Smo.

Biochem Biophys Res Commun 2019 Apr 19. Epub 2019 Apr 19.

College of Life Sciences, Shandong Agricultural University, Tai'an, Shandong, China. Electronic address:

The GPCR-like transmembrane protein Smoothened (Smo) is an indispensable transducer in Hedgehog (Hh) pathway, its hyperactivation leads to several human cancers, including non-small cell lung cancer (NSCLC). The mechanism governing Smo stability still remains elusive. Here, we perform a modifier screening in Drosophila, and find that the E3 ligase dHerc4 degrades dSmo. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X193075
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2019.04.113DOI Listing
April 2019
1 Read

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.

Clin Lung Cancer 2019 Mar 29. Epub 2019 Mar 29.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Introduction: Leptomeningeal metastasis (LM), still an area of unmet need, has frequently been observed in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Because the antitumor efficacy of systemic cytotoxic agents against LM is unclear, we explored the role of pemetrexed in the treatment of patients with LM from EGFR-mutant NSCLC.

Patients And Methods: We retrospectively reviewed the medical records of patients with LM from EGFR-mutant NSCLC treated between 2006 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.03.005DOI Listing

Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4.

Artif Cells Nanomed Biotechnol 2019 Dec;47(1):1595-1602

a Department of Thoracic Surgery , First People's Hospital of Yunnan Province , Kunming , China.

Long noncoding RNA, long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was showed to be involved in cancer development. However, the biological effect of LINC-PINT on non-small cell lung cancer (NSCLC) remains unknown. Here, we aimed to investigate the role and underlying mechanism of LINC-PINT in NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21691401.2019.1605371DOI Listing
December 2019

Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al.

Eur J Cancer 2019 Apr 19;114:25-26. Epub 2019 Apr 19.

Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA; The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.02.017DOI Listing

Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer.

Semin Thorac Cardiovasc Surg 2019 Apr 19. Epub 2019 Apr 19.

Department of Thoracic Surgery, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, 1-8-1 Jigyohama, Chuo-ku, Fukuoka 810-8563, Japan.

Background: Red blood cell distribution width (RDW) is a parameter measured in blood sample tests that reflects the variation in the volume of erythrocytes and used to differentiate an anemic state. The RDW has been used to predict a poor survival in various types of cancer; however, the prognostic impact of the RDW in resected pathological stage I non-small cell lung cancer (NSCLC) patients remains to be elucidated.

Methods: A total of 273 patients with resected pathological stage I NSCLC were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semtcvs.2019.04.011DOI Listing

microRNA-370 Promotes Cell Growth by Targeting WNK2 in Breast Cancer.

DNA Cell Biol 2019 Apr 22. Epub 2019 Apr 22.

Central Hospital of Zibo, Zhangdian District, Zibo, Shandong, China.

Aberrant expression of microRNA-370 (miR-370) has been found in many types of human cancers. In non-small cell lung cancer, miR-370 is a tumor suppressor with decreased expression. In prostate cancer, it is an oncogene with overexpression. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/dna.2018.4602
Publisher Site
http://dx.doi.org/10.1089/dna.2018.4602DOI Listing
April 2019
2 Reads

Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings.

Jpn J Clin Oncol 2019 Apr 22. Epub 2019 Apr 22.

Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan.

Objective: Post-marketing surveillance (PMS) was performed in Japan to obtain information on the safety and efficacy of crizotinib.

Methods: Target patients included almost all patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who were administered crizotinib. The observation period was 52 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz049DOI Listing

End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study.

Health Serv Res Manag Epidemiol 2019 Jan-Dec;6:2333392819841223. Epub 2019 Apr 10.

Laboratory of Biopharmaceutics-Pharmacokinetics, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.

Introduction: Lung cancer exerts a significant societal and health-care-related economic burden and chemotherapy drugs constitute a major factor of total direct cost. The aim of the present study was to assess the direct health-care cost of lung cancer in Greece by conducting a retrospective analysis on the last 6 months of life.

Methods: The present study was based on both the medical data and costs of treatment of deceased adult patients who suffered from terminal stage IIIB/IV lung cancer (non-small cell lung cancer and small cell lung cancer) during the last 6 months of their life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2333392819841223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458659PMC

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature.

Respir Med Case Rep 2019 6;27:100834. Epub 2019 Apr 6.

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of corticosteroid therapy. However, a subset of patients may suffer from severe pneumonitis, and the optimal treatment for this group is not known. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2019.100834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456450PMC

A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non-small-cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor.

Respirol Case Rep 2019 Jul 10;7(5):e00425. Epub 2019 Apr 10.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan.

Uncommon mutations account for 10-15% of epidermal growth factor receptor (EGFR) mutations in patients with non-small-cell lung cancer. Afatinib is currently the most efficient EGFR-tyrosine kinase inhibitor (TKI) against uncommon EGFR mutations. Here we report a 56-year-old woman presenting with persistent cough for one month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/rcr2.425DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456914PMC

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: Unusual presentation.

Ann Thorac Med 2019 Apr-Jun;14(2):161-163

Department of Medicine, Division of Pulmonary, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNEC) is an abnormal proliferation of pulmonary neuroendocrine cells that occur without underlying etiology. Here, we report a unique case of 55-year-old female with unusual presentation of DIPNECH and thymoma and on the background history of Crohn's disease that might point toward an autoimmune phenomenon. To the best of our knowledge, there were no previous reports of DIPNECH with either thymoma or Crohn's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/atm.ATM_159_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467018PMC

Can Nutritional Status Predict Overall Survival in Patients with Advanced Non-Small Cell Lung Cancer?

Nutr Cancer 2019 Apr 22:1-10. Epub 2019 Apr 22.

e Department of Clinical Oncology, College of Korean Medicine , Kyung Hee University , Seoul , Republic of Korea.

Medical records of patients with advanced non-small cell lung cancer (NSCLC) were retrospectively reviewed to examine the prognostic impact of nutritional status on survival. Age, sex, body mass index (BMI), Eastern Cooperative Oncology Group Performance Status (ECOG-PS), histologic tumor type, pulmonary comorbidities, white blood cell (WBC) count, C-reactive protein (CRP) level, and prognostic nutritional index (PNI) were assessed. Overall survival was calculated using Kaplan-Meier analysis and compared using log-rank testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01635581.2019.1598564DOI Listing